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ANAPLASTIC LARGE T-CELL LYMPHOMA: 10-YEAR EXPERIENCE
AT THE NATIONAL INSTITUTE OF NEOPLASTIC DISEASES,
LIMA – PERU
LINFOMA DE CÉLULAS GRANDES T ANAPLÁSICO: EXPERIENCIA DE 10 AÑOS EN EL INSTITUTO NACIONAL
DE ENFERMEDADES NEOPLÁSICAS, LIMA - PERÚ
Cristian Pacheco Román1,a, Mónica Calderón Anticona2,a, Carlos Barrionuevo 3,a,
Henry Gomez Moreno2,a

ABSTRACT
Introduction: Anaplastic Large T-Cell Lymphoma is an infrequent pathology, determined by the expression of
CD30, with diﬀerent characteristics in its presentation and being more aggressive according to ALK expression.
Objectives: The present study seeks to determine the epidemiological, clinicopathological, and prognostic
characteristics of patients with Anaplastic Large T-Cell Lymphoma. Methods: Descriptive, retrospective study
of patients diagnosed with Anaplastic Large T-Cell Lymphoma of the National Institute of Neoplastic Diseases
(INEN) between 2006 and 2016. Results: The pathology of 86 patients was analyzed and reviewed, 57% were
men and 33 % women; of the total population, 21.9% were positive for ALK, 48 of the patients were found in CD I
and II, and 36 between stages III and IV. 57 patients had low or low-intermediate risk, while 26 had highintermediate and high risk. The estimated overall survival was 40.8% at 5 years; in the group of patients with
ALK + it was 67.4%, and in the group with ALK-, it was estimated at 30.2%. Conclusions: Anaplastic Large T-Cell
Lymphoma is an aggressive disease with a heterogeneous distribution to age and slightly more frequent in
males, with ALK and the international prognostic index as important prognostic factors.
Keywords: Anaplastic Large Cell Lymphoma; Anaplastic Lymphoma Kinase; Survival rate. (Source: MeSH NLM)

RESUMEN
Introducción: El Linfoma de Células Grandes T Anaplásico es una patología infrecuente, determinada por la
expresión del CD30, con diferentes características en su presentación y ser de carácter más agresivos de
acuerdo a la expresión del ALK. Objetivos: El presente estudio busca determinar las características
epidemiológicas, clinicopatológicas y pronóstico de los pacientes con Linfoma de Células Grandes T
Anaplásico. Métodos: Estudio descriptivo, retrospectivo de pacientes diagnosticados con Linfoma de Células
Grandes T Anaplásico del Instituto Nacional de Enfermedades Neoplásicas (INEN) entre los años 2006 al 2016.
Resultados: Se analizaron y revisaron la patología de 86 pacientes, 57% fueron hombres y 33% mujeres, de la
población total 21.9% fueron positivos para ALK. 48 de los pacientes se encontraron en EC I y II y 36 entre
estadios III y IV. 57 pacientes presentaban riesgo bajo o intermedio bajo mientras que 26 entre riesgo
intermedio alto y alto. La sobrevida global estimada fue 40.8% a los 5 años, en el grupo de pacientes con ALK +
fue 67.4% y en el grupo con ALK- se estimó en 30.2%. Conclusiones: El Linfoma de Células Grandes T Anaplásico
es una enfermedad agresiva, con distribución heterogénea respecto a la edad y ligeramente más frecuente en
varones, con el ALK y el índice pronóstico internacional como factores pronósticos importantes.
Palabras clave: Linfoma Anaplásico de Células Grandes; Quinasa de Linfoma Anaplásico; Tasa de supervivencia
(Fuente: DeCS BIREME)
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INTRODUCTION

Diseases (INEN) in Lima, Peru 2006 and 2016. This will

Anaplastic Large T-Cell Lymphoma (ALCL), initially

allow to know the form of presentation in our

described in 1985 , belongs to the T-cell family and is a

population and thus be able to take the best

unique type of lymphoma strongly expressing the

management and monitoring option. In addition, it will

CD30 antigen. This neoplasm is relatively infrequent,

serve as the basis for future analyzes and improvements

found in around two to 8% of all non-Hodgkin's

in treatment.

(1)

lymphomas, between 10% to 20% of high-grade
lymphomas, and 16% of T-lymphomas (2).

METHODS
Study design type and area

According to the World Health Organization (WHO) (3) ,
the expression of Anaplastic Lymphoma Kinase 1 (ALK1)
determines the presence of two diﬀerent entities: ALCL

Descriptive, retrospective study of a patient diagnosed
with Anaplastic Lymphoma, diagnosed at the INEN
Lima, Peru, between 2006 and 2016.

ALK positive (+), which represents 70%, it is more
common in children and adolescents, males with a less
aggressive course and better prognosis; and ALCL ALK
negative (–), considered a provisional entity, more
common in adults, without gender predominance, low
incidence of systemic symptoms and worse prognosis
. Both entities share similar characteristics, especially

(4,5)

the morphological ones and the overexpression of
CD30, which allows them to be diﬀerentiated from the
rest of the peripheral T-cell lymphomas.

Population and sample
91 medical records were analyzed, having as inclusion
criteria all the patients 14 years of age or older, with a
pathological diagnosis of Anaplastic Large Cell
Lymphoma, of any location and without previous
treatment. Two patients under 14 years of age were
excluded, two referred as anaplastic lymphoma but
with no pathology in the INEN, and one with previous
treatment in another institution. Therefore, we worked
with the 86 medical records that met the inclusion
criteria.

The International Prognostic Index (IPI) is a tool used as

Variables and instruments

a predictive index for the survival of patients with non-

The anatomopathological diagnosis of Anaplastic
L a r g e C e l l Ly m p h o m a w a s m a d e u n d e r t h e
recommendations of the WHO (3) , which describes the
presence of large, pleomorphic lymphoid cells with
abundant cytoplasm and frequent presence of a
horseshoe nucleus (hallmark cell), with expression
intense CD30, and immunopositivity or not for ALK, this
diagnosis excludes B lymphomas with CD30 expression
(8,9)
. In addition, the epidemiological characteristics,
staging and survival of the patients were analyzed.

Hodgkin's lymphoma. In recent years, a prognostic
index for T-cell lymphoma (PIT) has been introduced,
which includes the compromise of bone marrow, which
is rare in ALCL, both indices are similar in this pathology
(6)

, so it has not yet been fully approved for ALCL.

Treatment continues to be combined chemotherapy
associated with anthracyclines (7) , which reaches up to
80% complete response, with relapse rates of
approximately 25%; in patients with residual disease

Procedures

(especially in mediastinal lymphomas) radiotherapy is

The pathological anatomy results of each medical
record, which included immunohistochemical studies
with expression mainly of CD30 (Clona Ver-Hz, Dako,
Denmark), ALK (Clona ALK1, Dako, D), CD3 (Policlonal
Dako Denmark), EMA (Clona E29, Dako D), CD45 (Clona
2B11, Dako, Denmark) and CD20 (Clona L26, Dako, D),
were re-evaluated and con rmed by an expert
pathologist.

indicated.
The present study seeks to determine the
epidemiological, clinical-pathological, and prognostic
characteristics of patients older than 14 years with
ALCL, diagnosed at the National Institute of Neoplastic .
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The epidemiological characteristics evaluated were
age, sex, origin, and patient quality of life using the
Eastern Cooperative Oncology Group (ECOG) scale,
date of diagnosis, date of the last consultation, and
survival status.

RESULTS
The characteristics of the patients are detailed in Table
1. There were 86 patients in the study with a mean age of
43 years (range, 15 to 88 years), of whom 49 (57.0%)
were men and 37 (43.0%) were men. .0%) women. More

For staging, imaging studies were analyzed, including

than 50% of patients had a good ECOG 1 performance

X-rays and tomography, bone marrow aspiration with

status. According to DHL levels, 48 (55.8%) patients had

bone biopsy, all re-evaluated by radiologists and

elevated status. According to ALK expression, 18

pathologists from our Institution, and then used the

(20.9%) patients were positive, 53 (61.6%) were

Ann Arbor Staging System (10).

negative, and 15 (17.4%) did not have this result.
According to the stage, 19 (22.1%) were stage I, 29

The following parameters were used to determine the

(33.7%) were stage II, 12 (14.0%) were stage III, and 24

International Prognostic Index (IPI)

(27.9%) were stage IV, in two ( 2.3%) patients, the stage is

(11)

, older than 60

years of age, patient quality of life, number of lymph

not speci ed.

node sites, clinical stage, extranodal involvement, and
lactate dehydrogenase above the normal value. The
patients received CHOP or CHOP-like chemotherapy as
a treatment scheme

. Response to treatment was

(12)

evaluated using the Response criteria of the American
Society of Clinical Oncology (13).

According to the international prognostic index, 34
(39.5%) were low risk (BR), 23 (26.7%) low intermediate
(IB), 20 (23.3%) high intermediate (IA), and 6 (7 .0%) high
risk (AR), in 3 (3.5%) patients the index is not speci ed
because they do not have the complete data recorded

Statistical analysis

in the histor y. 67 patients (79.6%) received

A descriptive analysis was performed through

chemotherapy, 3 (3.4%) radiotherapy, and 16 (17%) did

frequencies, percentages, and summary measures

not receive treatment; the causes were sepsis ( ve

(mean and range). For the analysis of progression-free

patients), no desire for therapy (four patients), and

survival, the follow-up time was considered from the
start date of the

rst treatment to the date of

recurrence/progression, death or last control; For the
analysis of overall survival, the follow-up time was

transfers to another institution ( six patients). Of the
patients who received chemotherapy, 24 (35.8%)
achieved complete response (CR), ten(14.9%) partial

considered from the start date of the rst treatment to

response (PR) and 33 (49.3%) no response and/or

the date of death or last control. In estimating survival,

disease progression.

the Kaplan-Meier method was used, and diﬀerences
between survival curves were tested with the logrank

Regarding the distribution of ALK+ and ALK- cases by

test. The selection of factors that increase the risk of

age groups, the T-test for independent samples shows

death was carried out through the Cox regression

that the average age for ALK + patients was signi cantly

model. A value p<0.05 was considered a signi cant
diﬀerence and risk. Statistical analysis was performed
using the SPSS 22.0 statistical system.

lower than that of ALK - patients (27.9 years vs. 47.4
years p<0.05). In the group of ALK+ patients, 25% were
under 17 years of age, 50% were under 22.5 years of age,

Ethical aspects

and 25% over 34 years of age. 01 distant value to the rest

Con dentiality of the identity of the patients and the

(atypical case) of a 58-year-old patient was identi ed. In

information in the medical records was guaranteed;

the ALK- group, 25% were under 30 years old, 50% were

likewise, the guidelines of the Declaration of Helsinki

under 50 years old, and 25% were over 62 years old; no

were met.

atypical cases were found.
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Table 1.
Characteristics

Characteristics of the patients.
n (%)

Age, years
Mean / Range
Sex

43 / [15-88]

Male

49 (57.0)

Female
Quality of Life (ECOG)

37 (43.0)

1

50 (58.1)

2

26 (30.2)

3

6 (7.0)

4
LHD (IU / L)

4 (4.7)

Normal

33 (38.4)

High

48 (55.8)

SEL
Bulky (tumor ≥10cm)

5 (5.8)

Yes

25 (29.1)

No

57 (66.3)

SEL
ALK

4 (4.7)

Negative
Positive
SEL
Clinical Stage
I
II
III
IV
SES
IPI
Low
Low Intermediate
High Intermediate
High

53 (61.6)
18 (20.9)
15 (17.4)
19 (22.1)
29 (33.7)
12 (14.0)
24 (27.9)
2 (2.3)
34 (39.5)
23 (26.7)
20 (23.3)
6 (7.0)

SES
Chemotherapy
Radiotherapy
No treatment

67 (79.6)

Infectious

16 (17.0)

3 (3.5)
3 (3.4)

Family disagreement

5

Lost sight/OI
Total

4
6
86 (100)

NSE: not speci ed.
DHL: Lactic dehydrogenase.
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The ve year progression-free survival (PFS) ranges for

20.9 % for intermediate IPI, and 0% for high risk;

ALCL ALK+ and ALK- patients were 62.2% and 20.7%,

something similar occurred with the PIT, which also

respectively (HR: 4.52; 95% CI, 1.6-12.74). ; p=0.004). The

showed a high risk of mortality in the high and

International Prognostic Index (IPI) (Figure 1) identi ed

intermediate-high group compared to the low and

diﬀerent risk groups across the entire cohort. 5-year PFS

intermediate-low group (HR: 6.25; 95% CI, 2.96-12.79;

was 56.8% for low IPI, 18.4% for low-intermediate,

p= 0.05).

Figure 1. Estimated progression-free survival curves by International Prognostic Index (IPI).
When performing multivariate analysis, including ALK
characteristics, DHL, stage and IPI, and choosing the
most in uential characteristics, it turned out that an
ALK negative has approximately six times more risk of
progression compared to an ALK positive, and that the
low intermediate IPI, high and high intermediate have
three, six and six times more risk of progression
compared to a low IPI, respectively (Table 2).
Regarding overall survival, the median follow-up time
was 72 months. Estimated overall survival one, three

and ve años fue de 61.4%, 46.8% y 40.8%, at one,
three, and 5 years was 61.4%, 46.8%, and 40.8%,
respectively. In the group of patients with ALK+, overall
survival at one, three, and 5 years was estimated at
85.6%, 77%, and 67.4%, respectively; and in the group
with ALK- it was estimated at 54.1%, 36.3% and 30.2% at
one, three, and 5 years, respectively. A signi cant
diﬀerence was found between both groups. In the
group of patients with normal LDH, overall survival at
one, three, and 5 years was estimated at 89.1%, 70%,
and 61%, respectively. In the group with high LDH it was
estimated at 41.5%, 28.9% and 25.3% at one, three, and
ve years, respectively, a signi cant diﬀerence was
found between both groups.
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Table 2. Univariate and multivariate analysis of the association of characteristics
with progression-free survival.
Univariate
Characteristics
ALK

n

Positive

15

Negative
DHL

43

Normal

27

High
Stage
I
II
III
IV
IPI

39

Low
Low Intermediate
Intermediate High
High

p

HR

Multivariate
p

1.00

1.00
0.004

4.52 (1.6-12.74)

0.001

14

7.28 (2.37-22.33)

2.32 (1.23-4.36)

0.404

1.48 (0.59-3.69)

1.00

0.914

1.00

1.42 (0.59-3.44)

0.671

1.06 (0.36-3.17)

0.299

0.75 (0.19-2.84)

25

0.437

8

0.338

1.71 (0.57-5.1)

21

0.028

2.74 (1.12-6.73)

1.92 (0.56-6.55)

1.00

1.00

26

p

HR
1.00

0.001 5.97 (2.02-17.59)

1.00

1.00
0.009

HR

Multivariate*

1.00

0.034

2.28 (1.07-4.88)

0.375

1.69 (0.53-5.38)

0.022 2.67 (1.15-6.22)

17

0.002

3.47 (1.58-7.65)

0.084

3.36 (0.85-13.24)

<0.05 6.14 (2.34-16.12)

5

0.002

5.64 (1.92-16.61)

0.107

3.45 (0.77-15.52)

0.003 5.58 (1.76-17.68)

19

* Variable selection method

In the group of patients with stage I, overall survival at
one, three, and 5 years was estimated at 73.3%, 66.7%,
and 66.7%, respectively; in the group, with stage II it was
estimated at 71.2%, 53.3% and 42.6% at 1, 3 and 5 years,
respectively; in the group of patients with stage III,
overall survival at 1, 3, and 5 years was estimated at 75%,
45%, and 22.5%, respectively. In the group with stage IV
it was estimated at 36.7%, 24.4% and 24.4% at one,
three, and 5 years, respectively. A signi cant diﬀerence
was found between the groups. In the group of patients
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with IPI BR, overall survival at one, three, and 5 years was
estimated at 85.2%, 70.4%, and 65.7%, respectively; in
the group with IPI IB it was estimated at 66.9%, 46.3%
and 30.9% at one, three, and 5 years, respectively; in the
group of patients with IPI IA, overall survival at one,
three, and 5 years was estimated at 31.4%, 15.7%, and
15.7%, respectively; and in the IPI AR group, it was
estimated at 0.0% at nine months. A signi cant
diﬀerence was found between the groups (Figure 2).
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In the multivariate analysis, including the ALK
characteristics, DHL, stage and IPI, it was found that
ALK-negative has a ve-fold higher risk of death

to ALK-positive and that the low intermediate, high
intermediate and high IPI have three, ten, and nine times
higher risk of death compared to a low IPI (Table 3).

Table 3. Univariate and multivariate analysis of the association of characteristics with overall survival.
Univariate
Characteristics
ALK
Positive

n

p

HR

Multivariate
p

1.00

15
0.015

HR
1.00

0.003

5.63 (1.77-17.94)

2.22 (0.94-5.28)

0.032

2.98 (1.09-8.08)

5.49 (2.35-12.81)

<0.05

10.37 (3.71-28.95)

8.87 (2.82-27.93)

<0.05

9.17 (2.64-31.94)

3.69 (1.29-10.63)

Negative
DHL

44

Normal

28

High
Stage

39

I

15

II

25

0.206

1.94 (0.69-5.38)

III

8

0.204

2.24 (0.65-7.76)

IV
IPI

21

0.005

4.31 (1.55-11.96)

Low

27

Low Intermediate

19

0.07

Upper intermediate 17
High
5

<0.05
<0.05

1.00
0.002

3.12 (1.53-6.35)
1.00

1.00

1.00
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DISCUSSION

In our analysis, it was shown that the complete response

ALCL is a lymphoma with an aggressive and

achieved after the rst line of chemotherapy has a

heterogeneous clinical course, with a higher prevalence

better prognosis and a longer overall survival time

in children and young adults. Most studies report a

compared to patients who only achieved a partial

better response to treatment in young patients,

response. The literature indicates that the partial or

reaching a response range between 60%-90%. Sibón et

complete response after the administration of

al. reported in patients under 40 years of age, survival

chemotherapy, based on the CHOP or CHOP like

regardless of ALK status (14,15). Recent analyzes promote

scheme, can reach up to 65%; in our study said the

high-dose chemotherapy followed by Stem Cell

response to the rst line of treatment reached up to

Transplantation to prolong survival time; e there, the

50.7%.

importance of the search and identi cation of
prognostic factors for selecting the most aggressive

The ve-year survival for ALK+ patients was 62.5%,

population to oﬀer them more intense and optimal

similar to the 60% reported by Savage et al; for ALK -

therapy regimens.

patients it was 29.6% lower than the 36% reported in
the same study, evidencing, also described in other

In our study, we analyzed the epidemiological,

studies, that ALCL ALK + is an important favorable factor

clinicopathological, and prognostic characteristics of

in survival (2) . It has been shown that ALK plays an

patients with ALCL. The median age of 40 years was

important lymphomatogenesis (5) , strongly suggesting

found, regardless of ALK status, which is somewhat
higher compared to other series where the median age
was less than 35 years (16,17) , the range of men/women
was 1, 3:1, similar to other published series with a range
of 1.6-1.8:1. Patients with ALK expression were more
frequent in the rst and second decades of life, with a
median age of 22 years, which is lower compared to
other publications such as that of Ferrari et al. 2012 (18)
where they present median age of 34 years.
Other studies, such as the one by Savage et al.(2) , found
t h a t A LC L A L K p o s i t i v e s c o m p r o m i s e s k i n ,
subcutaneous cellular tissue, and bone marrow. We

that its inhibition would be suﬃcient to attenuate the
growth and survival of ALCL ALK+ cells, considering it as
a potential molecular target in the therapy of this
disease and in others where its presence has been
demonstrated, such as lung cancer and in ammatory
myo broblastic tumor (20,21) .
A study showed that the better evolution of patients
with ALCL ALK+ may also be associated with higher
levels of apoptosis due to chemotherapeutic agents
than ALK- cells (22) , which would increase the greater
responses and better prognosis in these patients.

found three patients with visceral, hepatic, and splenic
compromise and only two patients with the

Other factors that could be considered prognostic

compromise of bone marrow.

factors were also identi ed: lactic dehydrogenase
above the normal value, the International Prognostic

Various studies consider ALCL a chemosensitive

Index, and the clinical stage

disease, in some cases even comparable to Diﬀuse

signi cance, while other works do not consider that

Large B-Cell Lymphoma, to treatment with the

these are independent factors (23) . We found positivity

indication of starting rst-line chemotherapy based on

for ALK as a prognostic factor and an international

anthracyclines

prognostic index with a signi cant statistical diﬀerence.

(12)

the standard scheme is CHOP, and in

(6)

, all with statistical

cases of relapses with schemes based on platinum.
Studies show an overall response between 70% and

The limitations of the study have been that it is a

80%

retrospective study and that 17% of the population did

(19)

, higher than that found in our study, where it

reached 50.7% after the rst line of treatment.
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CONCLUSIONS
ALCL is an aggressive disease with a heterogeneous
distribution for age and slightly more frequent in males,
where ALK expression can be considered a prognostic
factor (where its expression determines the existence of

aggressiveness) and the International Prognostic Index.
Treatment based on anthracyclines allows obtaining an
overall response greater than 50% with overall survival
of 38.5% at ve years.

two diﬀerent entities due to the age of presentation and
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